Lorenz Mayr,
Vice President
Lorenz is working as Vice President, Reagents & Assay Development with global responsibility for generation of biological reagents and assay development activities at AstraZeneca. This includes generation of proteins and cell lines for hit finding, hit-to-lead and lead optimisation activities including structure & biophysics for all therapeutic areas, generation of tool antibodies, transgenic animals, stem/primary cells as tools for target validation and lead optimisation. His department is responsible for the development of biochemical, cell-based and phenotypic assays at AstraZeneca.
Before that, he was working as Executive Director at Novartis in Basel/Switzerland, at Bayer in Leverkusen & Wuppertal/Germany and at the MIT/Whitehead Institute in Cambridge/MA (U.S.A.).
He has published more than 50 papers in peer-reviewed journals and serves on several editorial and scientific advisory boards, including two terms at the Board of Directors for SBS (2004-2011) and has been working as the Conference Chair of the MipTec Conference, Europe’s largest drug discovery event.
|
.png)
|
|
